Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  pirarubicin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-8 of 8 for your search:
Start Over
Phase II Pilot Study of Combination Chemotherapy with 5-FU/THP-Adriamycin/CTX in Patients with Metastatic Breast Cancer (Summary Last Modified 09/88)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 15 and over
Sponsor:
Protocol IDs: MDA-DM-87008, NCI-V88-0433
Phase II Study of Pirarubicin (THP) in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 11/88)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 75 or less
Sponsor:
Protocol IDs: EORTC-24873
Phase II Study of Pirarubicin in Patients with Unresectable Malignant Mesothelioma (Summary Last Modified 02/90)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: SCCC-8827, NCI-V89-0309
Phase II Study of Pirarubicin in Patients with Metastatic Adenocarcinoma of the Breast (Summary Last Modified 10/89)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: PCCC-8725, NCI-V89-0137
Phase II Study of Pirarubicin in Patients with Advanced Carcinoma of the Head and Neck (Summary Last Modified 10/89)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: PCCC-8726, NCI-V89-0138
Phase II Study of Pirarubicin in Patients with Advanced non-Small Cell Lung Cancer (Summary Last Modified 10/89)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: PCCC-8727, NCI-V89-0139
A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 12 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: SIM-65, NCT01002092
Start Over